Maze Therapeutics (MAZE) Misses Q4 EPS by 65c

Maze Therapeutics (NASDAQ: MAZE) reported Q4 EPS of ($0.65).

For earnings history and earnings-related data on Maze Therapeutics (MAZE) click here.

You May Also Be Interested In

• Citi initiates coverage of Maze Therapeutics with Buy rating
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
• H.B. Fuller (FUL) Tops Q3 EPS by 5c, Misses on Revenue; Offers FY26 EPS Guidance